A comparison of bilateral breast cancers in BRCA carriers Journal Article


Authors: Weitzel, J. N.; Robson, M.; Pasini, B.; Manoukian, S.; Stoppa-Lyonnet, D.; Lynch, H. T.; McLennan, J.; Foulkes, W. D.; Wagner, T.; Tung, N.; Ghadirian, P.; Olopade, O.; Isaacs, C.; Kim-Sing, C.; Møller, P.; Neuhausen, S. L.; Metcalfe, K.; Sun, P.; Narod, S. A.
Article Title: A comparison of bilateral breast cancers in BRCA carriers
Abstract: Background: Women with breast cancer and a BRCA mutation have a high risk of developing a contralateral breast cancer. It is generally believed that the two cancers represent independent events. However, the extent of concordance between the first and second tumors with respect to hormone receptor expression and other pathologic features is unknown. Purpose: To determine the degree of concordance of estrogen receptor (ER) status, tumor grade, and histology in tumors from women with bilateral breast cancer and a BRCA mutation. Subjects and Methods: Women with a history of bilateral invasive breast cancers were selected from an international registry of women with BRCA1 or BRCA2 mutations. Medical records were reviewed to document the characteristics of each cancer and the treatments received. Results: Data were available for 286 women with bilateral breast cancer and a BRCA mutation (211 BRCA1; 75 BRCA2). The mean interval between first and second tumor was 5.1 years. The two tumors were concordant more often than expected for ER status (P < 0.0001) and for grade (P < 0.0001), but not for histology (P = 0.55). The ER status of the first tumor was highly predictive of the ER status of the second tumor (odds ratio, 8.7; 95% confidence interval, 3.5-21.5; P < 0.0001). Neither age, menopausal status, oophorectomy nor tamoxif en use was predictive of the ER status of the second tumor. Conclusions: There is strong concordance in ER status and tumor grade between independent primary breast tumors in women with a BRCA mutation. The excess concordance may be due to common risk factors, genetic variation, or the existence of a preneoplastic lesion that is common to both tumors. Copyright © 2005 American Association for Cancer Research.
Keywords: adult; controlled study; human tissue; middle aged; gene mutation; major clinical study; histopathology; cancer risk; neoplasm staging; cancer grading; breast cancer; ovariectomy; aromatase inhibitor; risk factors; breast neoplasms; brca1 protein; brca2 protein; heterozygote; cancer therapy; genes, brca1; genes, brca2; medical record; tamoxifen; receptors, estrogen; neoplasms, second primary; dna mutational analysis; second cancer; estrogen receptor; menopause; age of onset
Journal Title: Cancer Epidemiology Biomarkers and Prevention
Volume: 14
Issue: 6
ISSN: 1055-9965
Publisher: American Association for Cancer Research  
Date Published: 2005-06-01
Start Page: 1534
End Page: 1538
Language: English
DOI: 10.1158/1055-9965.epi-05-0070
PUBMED: 15941968
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 24" - "Export Date: 24 October 2012" - "CODEN: CEBPE" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Mark E Robson
    676 Robson